

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
24 July 2003 (24.07.2003)

PCT

(10) International Publication Number
WO 03/059393 A1

- (51) International Patent Classification⁷: **A61K 47/48**,
A61P 1/04, A61K 31/4439
- (21) International Application Number: PCT/EP03/00242
- (22) International Filing Date: 13 January 2003 (13.01.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
02000288.7 15 January 2002 (15.01.2002) EP
02006454.9 22 March 2002 (22.03.2002) EP
- (71) Applicant (for all designated States except US): **ALTANA PHARMA AG** [DE/DE]; Byk-Gulden-Str. 2, 78467 Konstanz (DE).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GIORDANO, Ferdinando** [IT/IT]; Via Di Vittorio, 4, I-27020 TORRE D'ISOLA, PAVIA (IT). **MARZOCCHI, Lucia** [IT/IT]; Via Casale 20, Grondola di Pontremoli, I-54027 PONTREMOLI, MASSA CARRARA (IT). **MOYANO, Jose, Ramon** [ES/ES]; Calle Leon XIII, 41092 SEVILLE (ES). **ROSSI, Alessandra** [IT/IT]; Via Don Camillo Ruta, 1, I-27049 STRADELLA, PAVIA (IT).
- (74) Common Representative: **ALTANA PHARMA AG**; Byk-Gulden-Strasse 2, 78467 Konstanz (DE).
- (81) Designated States (*national*): AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, TN, UA, US, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR).
- Declarations under Rule 4.17:**
- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AL, AU, BA, BR, CA, CN, CO, CU, DZ, EC, GE, HR, ID, IL, IN, IS, JP, KR, LT, LV, MA, MK, MX, NO, NZ, PH, PL, RO, SG, TN, UA, VN, YU, ZA, ZW, Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR)
 - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations
 - as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) for all designations of inventorship (Rule 4.17(iv)) for US only
- Published:**
- with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PANTOPRAZOLE CYCLODEXTRIN INCLUSION COMPLEXES

(57) Abstract: An inclusion complex formed from pantoprazole and cyclodextrin is described.

BEST AVAILABLE COPY

WO 03/059393 A1

Pantoprazole Cyclodextrin Inclusion Complexes

Technical field

The present invention relates to the field of pharmaceutical technology and describes pantoprazole cyclodextrin inclusion complexes.

Background art

H⁺/K⁺-ATPase inhibitors, in particular pyridin-2-ylmethylsulfinyl-1H-benzimidazoles like those disclosed, for example, in EP-A-0 005 129, EP-A-0 166 287, EP-A-0 174 726 and EP-A-0 268 956 are important in the therapy of disorders originating from increased gastric acid secretion. Examples of active ingredients from this group which are commercially available are 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: omeprazole), 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: pantoprazole), 2-[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl)methylsulfinyl]-1H-benzimidazole (INN: lansoprazole) and 2-[[4-(3-methoxypropoxy)-3-methylpyridin-2-yl]methylsulfinyl]-1H-benzimidazole (INN: rabeprazole).

WO86/00913 discloses to form a stable complex by mixing and reacting omeprazole with β -cyclodextrin in 96% ethanol and cooling the reactant. WO93/13138 is related to a method for preparing enteric coated oral drugs containing acid-unstable compound, in particular an enteric-coated oral drug prepared in the form of acid-stable dosage unit inclusion complex formed by reacting benzimidazole derivative, acid-unstable compound, with cyclodextrin in alkaline solution. WO9638175 is related to a stabilized composition comprising an antiulcerative benzimidazole compound, particularly a proton pump inhibitor and a branched cyclodextrinic carboxylic acid. WO99/62958 is related to alkylated cyclodextrin derivatives and their use as carriers for medicaments. WO98/40069 describes pharmaceutical formulations comprising a benzimidazole and as excipients, at least one cyclodextrin and at least one amino acid. EP-A-1018340 discloses the simultaneous reaction of a benzimidazole derivative with one or more amino acids and one or more cyclodextrins as a process to obtain an inclusion complex of a salt of a benzimidazole derivative.

Description of the invention

Surprisingly it has now been found that by reaction of pantoprazole with a cyclodextrin, inclusion complexes are obtained with increased overall solubility for pantoprazole brought about by the formation of soluble pantoprazole-cyclodextrin complexes.

Subject of the present invention is a pantoprazole cyclodextrin inclusion complex.

Pantoprazole in connection with the invention refers to 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole. Pantoprazole is a chiral compound. The term pantoprazole in connection with the invention also encompasses the pure enantiomers of pantoprazole and their mixtures in any mixing ratio. Pure enantiomers which may be mentioned by way of example are (-)-pantoprazole and (+)-pantoprazole. Pantoprazole may be present as such or, preferably, in the form of its salts with bases. Examples of salts with bases which may be mentioned are sodium, potassium, magnesium or calcium salts. In a preferred embodiment pantoprazole refers to pantoprazole sodium or pantoprazole magnesium. If pantoprazole is isolated in crystalline form, it may contain variable amounts of solvent. The term pantoprazole therefore also represents according to the invention all solvates, in particular all hydrates, of pantoprazole and its salts.

In a preferred embodiment pantoprazole refers to pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium sesquihydrate or pantoprazole magnesium dihydrate.

Cyclodextrin in connection with the invention preferably refers to α -, β - or γ -cyclodextrin, their hydrates, mixtures of α -, β - or γ -cyclodextrin or derivatives of α -, β - or γ -cyclodextrin such as alkyl or hydroxyalkyl derivatives. In a preferred embodiment of the invention cyclodextrin refers to β -cyclodextrin (β -CD), hydroxypropyl- β -cyclodextrin (HP β -CD), the sodium salt of sulfobutylether β -cyclodextrin (SB β -CD) or hydroxyethyl- β -cyclodextrin.

In a preferred embodiment according to the invention the pantoprazole cyclodextrin inclusion complex refers to a 1/1 (pantoprazole/cyclodextrin) complex. The pantoprazole cyclodextrin inclusion complexes may be produced for example by standard procedures for preparation of compound-cyclodextrin inclusion complexes. Such procedures are for example disclosed in WO86/00913, WO93/13138, WO96/38175 or by Duchene (in Proceedings of the Fourth International Symposium on Cyclodextrines, 265-275, 1988 by Kluwer Academic Publishers; eds. O. Huber and J. Szejtli). Inclusion compounds are usually prepared in liquid medium, but they can also be obtained in the solid phase. In one embodiment of the invention the inclusion complex is obtained by reacting pantoprazole with the cyclodextrin in a suitable solvent. In a preferred embodiment of the invention the solvent is an aqueous solvent or a solvent which essentially consists of an aliphatic alcohol, preferably ethanol. The inclusion complex may then be obtained by precipitation or freeze drying. In one embodiment the inclusion complex is obtained according to the method described in WO86/00913.

The pantoprazole cyclodextrin inclusion complexes of the invention can then be used as a basis for the production of the administration forms according to the invention. Administration forms according to the invention which may be mentioned, to which the preparations can be processed, are, for example, suspensions, gels, tablets, coated tablets, multicomponent tablets, effervescent tablets, rapidly disintegrating tablets, powders in sachets, sugar-coated tablets, capsules or alternatively suppositories. The

excipients which are suitable for the desired administration forms are familiar to the person skilled in the art on the basis of his/her expert knowledge. Due to the increased solubility of pantoprazole in the pantoprazole cyclodextrin inclusion complex administration forms containing such inclusion complex have improved active compound bioavailability properties.

Suitable administration forms are for example disclosed in WO92/22284, WO97/02020, EP-A-0 244 380, WO96/01623, WO96/01624, WO96/01625 or WO97/25030.

The administration forms (also referred to as pharmaceutical formulations) according to the invention comprise the pantoprazole or pantoprazole cyclodextrin inclusion complex in the dose customary for the treatment of the particular disorder. The pantoprazole cyclodextrin inclusion complex of the invention can be employed for the treatment and prevention of all disorders which are regarded as treatable or preventable by the use of pyridin-2-ylmethylsulfinyl-1H-benzimidazoles. In particular, the pantoprazole cyclodextrin inclusion complex of the invention can be employed for the treatment or prophylaxis of gastric disorders such as peptic ulcer disease or other disorders associated with gastric hyperacidity such as gastro-oesophageal reflux disease, Zollinger-Ellison Syndrome and dyspepsia (see e.g. MARTINDALE – The complete Drug Reference, Pantoprazole, MICROMEDEX® Healthcare Series Vol.113, 2002). Administration forms such as tablets contain between 1 and 500 mg, preferably between 5 and 60 mg, of an acid-labile proton pump inhibitor. Examples which may be mentioned are tablets which contain 10, 20, 40 or 50 mg of pantoprazole. The daily dose (e.g. 40 mg of active ingredient) can be administered, for example, in the form of a single dose or by means of a plurality of doses of the tablets of the invention (e.g. 2 x 20 mg of active ingredient).

EXAMPLE

5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole sodium sesqui-hydrate β -cyclodextrin inclusion complex

1.73 g of 5-difluoromethoxy-2-[(3,4-dimethoxy-2-pyridinyl)methylsulfinyl]-1H-benzimidazole sodium sesquihydrate, 5.67 g β -cyclodextrin and 20 ml of ethanol (96%) are heated to 30 to 32° C and stirred for 15 hours. The mixture is cooled to 10 ° C within 3 hours, filtered and the precipitate washed with ethanol (10 ° C). After drying under reduced pressure the title compound is obtained.

COMPLEXATION STUDIES OF PANTOPRAZOLE WITH CYCLODEXTRINS

Methods: Various solutions of the different cyclodextrins taken into consideration were prepared in phosphate buffer solution pH 7 at known concentrations and used to create saturated solutions of pantoprazole. After equilibration, these saturated solutions were filtered through MFTM membrane filters (pore size 0.45 μ m), appropriately diluted with phosphate buffer solution and subjected to uv/vis spectrophotometric analysis. The cyclodextrin solutions prepared with phosphate buffer ranged from concentrations of 0% p/v up to 1.8% p/v for β CD, 20% p/v for HP β CD.

Results: In both cases, the solubility of pantoprazole increased markedly with increasing cyclodextrin concentration. In the presence of β CD pantoprazole's solubility rose to a four fold maximum with respect to its solubility in phosphate buffer whereas when equilibrated with HP β CD, pantoprazole showed an outstanding increase in its solubility reaching over seventy times that in phosphate buffer solution.

Conclusions: The phase solubility studies with β CD and HP β CD were both characterised by an overall increase in pantoprazole's solubility brought about by the formation of soluble pantoprazole/cyclodextrin complexes. In the case of β CD phase solubility studies, the increase observed followed a typical A_p pattern commonly described by Higuchi-Connor, indicating the formation of complexes with an order higher than one. Pantoprazole's behaviour with HP β CD also followed a typical Higuchi-Connor's A_p pattern characterised further by an initially gradual increase in solubility.

Complexation studies on pantoprazole, both in its saline form as a sodium salt (PNTNa) and as a free acid (PNTH), were carried out with β -cyclodextrin (β -CD), hydroxypropyl- β -cyclodextrin (HP β -CD) and the sodium salt of sulfobutylether β -cyclodextrin (SB β -CD). A second study was carried to define the Phase-solubility behaviour of PNTH when equilibrated with aqueous solutions of β -CD, HP β -CD and SB β -CD prepared in phosphate buffer solution (pH 7).

Methods of Sample Preparation

Preparation of PNTH

Pantoprazole sodium salt was used as a starting material. PNTH was obtained via drop by drop acidification of an aqueous solution of the sodium salt with acetic acid (0.1N) until pH 7.5 was reached. The resulting milky white suspension was filtered with use of the Buchner apparatus and the resulting solid was left to dry.

Complexation Studies

Kneading

Inclusion complexes of pantoprazole, both the sodium salt (PNTNa) and the undissociated form (PNTH), with β -cyclodextrin (β -CD), hydroxypropyl- β -cyclodextrin (HP β -CD) and the sodium salt of sulfobutylether β -cyclodextrin (SB β -CD) were prepared via kneading 1:1 and 1:2 molar physical mixtures. A phosphate buffer or a 1:1 hydroethanolic solution were used as binding solutions respectively for the preparation of the inclusion complexes of PNTNa and PNTH.

Freeze Drying

The technique of Freeze-Drying was applied to the preparation of 1:1 molar inclusion complexes of PNTH and PNTNa respectively with HP β -CD.

In preparing the PNTNa: HP β -CD 1:1 molar sample, which was then to be subjected to freeze drying, the exact quantity of HP β -CD was first dissolved in the minimum amount of distilled water necessary (1.5 ml/mg ca) and stirred continuously. The exact amount of weighed PNTNa was then added in small portions. After complete solubilization of the drug, the sample was frozen in liquid nitrogen and freeze dried (-70°C , 760 torr) for 12 hours.

The PNTH: HP β -CD 1:1 molar sample was prepared differently according to the following method. Once again, the exact quantity of HP β -CD was first dissolved in the minimum amount of distilled water necessary (1.5 ml/mg ca) and stirred continuously. The exact amount of weighed PNTH was then added in small portions but its solubilization was helped along by the addition of acetone. The total volume of acetone added in relation to the amount of water used to solubilize HP β -CD was 1:1. The sample was then frozen in liquid nitrogen and freeze dried (-70°C , 760 torr) for 12 hours.

PHASE-SOLUBILITY STUDIES OF PNTH WITH NATURAL AND MODIFIED CYCLODEXTRINS.

The solubility of PNTH in phosphate buffer solution at pH 7 was determined using a previously constructed absorbance vs. concentration calibration curve.

A known amount of PNTH was suspended in cyclodextrin solutions of different concentrations ranging from; 0 to 1.8% (p/v) for β -CD, 0 to 20% (p/v) for H-P β -CD and 0 to 15% (p/v) for SB- β -CD. The resulting suspension was filtered using a PTFE 0.45 μ filter, adequately diluted and then subjected to UV spectrophotometric analysis. The concentration of PNTH in the corresponding sample was then calculated referring to the relevant PNTH calibration curve.

Characterization Techniques

Complexation Studies

Thermal traces were obtained using a Mettler DSC 821⁹ module. FTIR spectra were carried out on KBr discs in the 400-4000 cm⁻¹ range (Jasco FT-300-IE). The Freeze Dryer used was a Pirani 10 Edwards Modulyo model. Powder X-ray diffractograms were recorded using a Bruker D5005 Diffractometer.

Phase-solubility Studies

UV-VIS spectra were recorded on a Jasco V570 Spectrophotometer.

Results

Phase-solubility Studies

A. Phase-solubility Curve of PNTH with β -CD in Phosphate Buffer Solution pH 7.

The Phase-solubility curve (Figure 1) follows a typical Higuchi-Connor pattern of type A_L. In fact, pantoprazole presents a linear increase in its apparent solubility when equilibrated with solutions of β -CD, reaching up to four times its solubility in phosphate buffer alone (from 0.56 mmol/L up to 2.25 mmol/L).




Figure 1.

B. Phase-solubility Curve of PNTH with HP β -CD in Phosphate Buffer Solution pH 7

Even in this case, the Phase Solubility curve (Figure 2) follows a typically linear Higuchi-Connor pattern. In fact, the increase observed in the apparent solubility of pantoprazole when equilibrated with solutions of HP β -CD, reaches up to 36 times that in phosphate buffer alone (from 0.56 mmol/L up to 17.8 mmol/L).




Figure 2.

C. Phase-solubility Curve of PNTH with SB β -CD in Phosphate Buffer Solution pH 7

In this case, the solubility of pantoprazole increases linearly when equilibrated with solutions of SB β -CD, and the Phase Solubility curve (Figure 3) shows that its apparent solubility increases twenty fold with respect to its value in phosphate buffer alone (from 0.56 mmol/L up to 9.3 mmol/L).




Figure 3.

Complexation Studies of samples prepared by kneading

Differential Scanning Calorimetry (DSC) was first used to characterise both the physical mixtures and the solid phases obtained after wetting and kneading. In none of the cases did we succeed in obtaining an inclusion complex using the technique of kneading. In fact, the DSC traces showed a first broad endothermic peak below 100 °C corresponding to cyclodextrin dehydration, and a second sharp endothermic peak either at 134 °C for PNTNa or at 144 °C for PNTH due to fusion.

Complexation Studies of samples prepared via freeze drying

The samples obtained via freeze drying both had a fluffy white foam-like consistency. Thermal analysis of these samples demonstrated, by the absence of the characteristic endothermic peaks of fusion of PNTNa and PNTH, that complexation had effectively occurred. The PNTH- HP β -CD 1:1 inclusion complex was extremely deliquescent. Powder X-ray diffractograms of the PNTNa: HP β -CD 1:1 inclusion compound proved it to have an amorphous solid structure.

Conclusions

- 1) Phase-solubility studies have shown that with all three CDs used, a notable increase in the apparent solubility of PNTH in phosphate buffer solution was observed.
- 2) Inclusion complexation was not achieved through kneading.
- 3) Freeze-drying permitted the preparation of an amorphous solid phase with HP β -CD and PNTNa from their aqueous solution.

Claims

1. Inclusion complex formed of pantoprazole, a salt of pantoprazole with a base, an enantiomer of pantoprazole or a salt of an enantiomer of pantoprazole and cyclodextrin.
2. Inclusion complex according to claim 1 formed of pantoprazole sodium sesquihydrate (= pantoprazole sodium x 1.5 H₂O), (-)-pantoprazole sodium sesquihydrate or pantoprazole magnesium dihydrate.
3. Inclusion complex according to claim 1 or 2, wherein the cyclodextrin is β -cyclodextrin.
4. Method for preparation of an inclusion complex according to any of claims 1 to 3 by reacting pantoprazole with the cyclodextrin in a suitable solvent.
5. Method according to claim 4, wherein the solvent is essentially ethanol.
6. Inclusion complex obtainable according to claim 4.
7. Inclusion complex according to claim 1, which is a 1/1 (pantoprazole/cyclodextrin) inclusion complex.
8. Administration form comprising an inclusion complex according to any of claims 1 to 3 together with suitable pharmaceutical auxiliaries.
9. Inclusion complex according to any of claims 1 to 3 for the treatment or prophylaxis of diseases of disorders originating from increased gastric acid secretion.
10. Method of treating or preventing a condition treatable or preventable with a pyridin-2ylmethylsulfinyl-1H-benzimidazole, which comprises administering to a subject prone to or afflicted with a condition a pharmaceutically acceptable administration form according to claim 8 comprising an effective amount of the pantoprazole inclusion complex.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00242

A. CLASSIFICATION OF SUBJECT MATTER
 IPC 7 A61K47/48 A61P1/04 A61K31/4439

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, CHEM ABS Data, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 96 38175 A (OGAWA YASUAKI ; ISHIGURO TOSHIHIRO (JP); NAKAMICHI MASANARI (JP); T) 5 December 1996 (1996-12-05) cited in the application page 22, line 17; claim 1 ---	1-10
X	WO 99 62958 A (JANSSEN PHARMACEUTICA NV ; KONDO AKIRA (JP); UEKAMA KANETO (JP); KA) 9 December 1999 (1999-12-09) page 5, line 5-7 page 15, line 4,5 ---	1-10
X	EP 1 018 340 A (TECNIMEDE SOCIEDADE TECNICO ME) 12 July 2000 (2000-07-12) page 5; claim 2 --- -/--	1-10

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *G* document member of the same patent family

Date of the actual completion of the international search

1 April 2003

Date of mailing of the international search report

10/04/2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
 NL - 2280 HV Rijswijk
 Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
 Fax: (+31-70) 340-3016

Authorized officer

Steendijk, M

INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 03/00242

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 40069 A (HEXAL AG ;KLOKKERS KARIN (DE); FISCHER-WILFRIED (DE); KUTSCHERA MA) 17 September 1998 (1998-09-17) page 5, line 14 -----	1-10
A	WO 93 13138 A (SUNKYONG IND LTD) 8 July 1993 (1993-07-08) cited in the application page 3, line 4-8; claim 2 -----	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 03/00242

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9638175	A	05-12-1996	AU 5780696 A WO 9638175 A1 JP 9048730 A	18-12-1996 05-12-1996 18-02-1997
WO 9962958	A	09-12-1999	AU 3954799 A EP 1084149 A1 WO 9962958 A1 JP 2002517521 T	20-12-1999 21-03-2001 09-12-1999 18-06-2002
EP 1018340	A	12-07-2000	EP 1018340 A1 ES 2149750 T1	12-07-2000 16-11-2000
WO 9840069	A	17-09-1998	WO 9840069 A2 AT 209491 T AU 731186 B2 AU 7207098 A BR 9808581 A DE 69802688 D1 DE 69802688 T2 DK 991407 T3 EP 0991407 A2 JP 2001518083 T NO 994409 A NZ 337592 A PL 335571 A1 SI 991407 T1 SK 120999 A3 US 6248758 B1	17-09-1998 15-12-2001 29-03-2001 29-09-1998 30-05-2000 10-01-2002 01-08-2002 25-03-2002 12-04-2000 09-10-2001 21-10-1999 26-01-2001 08-05-2000 30-04-2002 12-09-2000 19-06-2001
WO 9313138	A	08-07-1993	BR 9207000 A CA 2127111 A1 CN 1076124 A , B DE 69222950 D1 DE 69222950 T2 EG 20115 A EP 0619825 A1 ES 2111148 T3 HU 70494 A2 JP 2662518 B2 JP 7506088 T WO 9313138 A1 KR 9608231 B1 MX 9207676 A1 RU 2105773 C1 US 5399700 A	28-11-1995 08-07-1993 15-09-1993 04-12-1997 28-05-1998 31-07-1997 19-10-1994 01-03-1998 30-10-1995 15-10-1997 06-07-1995 08-07-1993 21-06-1996 01-06-1993 27-02-1998 21-03-1995

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.